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Aims The aim of this study is to develop models to aid the decision to prolong dual antiplatelet therapy (DAPT) that re-
quires balancing an individual patient’s potential benefits and harms.
...................................................................................................................................................................................................
Methods
and results
Using population-based electronic health records (EHRs) (CALIBER, England, 2000–10), of patients evaluated 1 year
after acute myocardial infarction (MI), we developed (n= 12 694 patients) and validated (n= 5613) prognostic models
for cardiovascular (cardiovascular death, MI or stroke) events and three different bleeding endpoints. We applied trial ef-
fect estimates to determine potential benefits and harms of DAPT and the net clinical benefit of individuals. Prognostic
models for cardiovascular events (c-index: 0.75 (95% CI: 0.74, 0.77)) and bleeding (c index 0.72 (95% CI: 0.67, 0.77))
were well calibrated: 3-year risk of cardiovascular events was 16.5% overall (5.2% in the lowest- and 46.7% in the
highest-risk individuals), while for major bleeding, it was 1.7% (0.3% in the lowest- and 5.4% in the highest-risk patients).
For every 10 000 patients treated per year, we estimated 249 (95% CI: 228, 269) cardiovascular events prevented and
134 (95% CI: 87, 181) major bleeding events caused in the highest-risk patients, and 28 (95% CI: 19, 37) cardiovascular
events prevented and 9 (95% CI: 0, 20) major bleeding events caused in the lowest-risk patients. There was a net clinical
benefit of prolonged DAPT in 63–99% patients depending on how benefits and harms were weighted.
...................................................................................................................................................................................................
Conclusion Prognostic models for cardiovascular events and bleeding using population-based EHRs may help to personalise de-
cisions for prolonged DAPT 1-year following acute MI.
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Introduction
Among patients who survived a year since their last acute myocardial
infarction (MI), subsequent major cardiovascular events, all-cause mor-
tality and major bleeding risks are high.1,2 In unselected populations in
USA, Sweden, England, and France, 20% of such patients experienced
subsequent MI, stroke, or died during the following 3 years.2
Prolonged secondary prevention therapy in such patients is already
recommended for four classes of drugs (statins, beta-blockers, ACE in-
hibitors, and aspirin). Recent trials3,4 examined addition of an extra
antiplatelet. The PEGASUS-TIMI 54 trial4 found prolonged dual antipla-
telet therapy (DAPT) using aspirin and ticagrelor compared with as-
pirin alone in patients 1–3 years since their last acute MI reduced the
risk of cardiovascular death, stroke, or MI by 16% but increased major
bleeding two-fold. In light of this evidence, 2015 European Society of
Cardiology guidelines recommend prolonged DAPT may be ‘con-
sidered after careful assessment of ischaemic and bleeding risks’.5,6
How to make this ‘careful assessment’ is unclear. Risk prediction
modelling has been proven invaluable in conditions such as atrial fibril-
lation where similar decisions on benefits and harm need to be
weighed.7 Indeed, such models for bleeding and subsequent MI have
been developed to guide use of bivalirudin,8 the choice of P2Y12 inhibi-
tor,9 and duration of DAPT.10,11 An existing model intended to guide
the duration of DAPT is based on patients undergoing drug eluting
stent placement and selected into a trial and uses patient characteris-
tics at the time of percutaneous coronary intervention.11 Currently,
no prognostic models evaluate the long-term risks of bleeding and car-
diovascular events using updated clinical information 1 year after acute
MI, to support the key clinical decision on prolonging DAPT.
In this context, unselected populations are important to provide real-
istic estimates of long-term cardiovascular and bleeding risks; these esti-
mates are often substantially higher than those observed in the placebo
arms of trials.12–14 Linked electronic health records (EHRs) are ideal
sources of data to derive such ‘real-life’ estimates of risks and harms, at
scale. The CALIBER dataset,15 validated for cardiovascular prognostic
research,16–18 is a 2 million person resource of linked primary–second-
ary and mortality data in England including 18 307 MI survivors.
Among these stable MI survivors, we sought to first, develop and
validate prognostic models for major cardiovascular and bleeding
events. We used prognostic factors present 1 year following acute
MI and widely recorded as a part of guideline recommended care.
Second, to demonstrate how predicted benefits and harms may aid
treatment and clinical decisions, we applied PEGASUS-TIMI 54 trial4
relative risks of efficacy and safety to estimate potential numbers of
cardiovascular events prevented and harms caused by prolonged
DAPT, and net clinical benefits for individuals.
Methods
The models were developed and validated in line with Transparent
Reporting of a multivariable prediction model for Individual Prognosis Or
Diagnosis (TRIPOD) guidelines19 (see Supplementary material online,
Table S1).
Linked EHRs
We used the CALIBER (ClinicAl research using LInked Bespoke and
Electronic health Records) research platform, consisting of EHR linkages
between primary care data (Clinical Practice Research Datalink (CPRD)),
secondary care data (Hospital Episode Statistics), disease registry data
(Myocardial Ischaemia National Audit Project), and cause-specific mortal-
ity (Office for National Statistics) in England.15 The 4% sample of
England’s population in CPRD available for linkage is unselected, repre-
sentative in terms of age, sex, and overall mortality.20–22 Furthermore,
there is extensive evidence of risk factor and cardiovascular and non-
cardiovascular disease endpoint validity in CALIBER.16–18,23–27 The study
was approved by the Independent Scientific Advisory Committee of the
Medicines and Health care products Regulatory Agency in the UK and
the MINAP Academic Group.
Study population
Patients in CALIBER alive 1 year after their last acute MI (i.e. their index
acute MI) were included in the study. We studied patients from 2000 to
2010, before the introduction of ticagrelor, and when prolonged DAPT
was rare. Follow-up started at 1 year after index acute MI, and patients
were censored at the earliest date of the endpoints of interest, primary
care practice transfer, death, or 5 years of follow-up. We evaluated pre-
scriptions indicating prolonged clopidogrel use in follow up (defined in
Supplementary material online, Table S2) in our cohort to ensure they
were untreated with long-term DAPT i.e. the decision our models aimed
to aid. Patients were split into model development and validation cohorts
using a pre-specified geographical divide.28 The North of England has
well-documented higher rates of cardiovascular mortality compared with
the South.29 Based on the 10 administrative areas in the National Health
Service, we chose 6 in the South for model development cohort and 4 in
the North for model validation cohort.
Potential prognostic factors
In model development, we considered a priori prognostic factors including
demographics, behaviours, cardiovascular and non-cardiovascular medical
history, medications, and clinical biomarkers. Each patient’s most recent
biomarker records in the year from index acute MI to follow-up start
were used. Medications were defined as having>_1 prescription of a drug
in the year prior to follow-up start. As a patient’s risk profile evolves with
time (risk at index event and at one year may differ), we also analysed risk
characteristics at the time of hospital discharge from index acute MI.
Details on data sources and EHR phenotypes for prognostic factors are
available at the CALIBER online portal (https://www.caliberresearch.org/
portal/, 10 January 2017) and see Supplementary material online, Table S2.
Endpoints
The primary endpoint relating to potential benefits of prolonged DAPT,
a composite of cardiovascular death, MI, or ischemic or unspecified stroke,
have validated phenotypes in CALIBER.16,17,23 For examining potential
harms of prolonged DAPT, we evaluated three severe bleeding endpoints
with differing incidence: (1) fatal or hospitalised bleeding; (2) CALIBER
major bleeding (a composite of fatal bleeding, intracranial bleeding, hospital-
ised bleeding with length of stay exceeding 14 days and bleeding requiring
transfusion); and (3) fatal or intracranial bleeding (see Supplementary mater
ial online, Table S3). We also evaluated models for all-cause mortality.
Statistical analysis
Model development
We evaluated associations between endpoints and prognostic factors using
proportional hazards models with Weibull baseline hazards. Univariable
models were used to detect non-linear trends and inform inclusion of
prognostic factors in multivariable models. Non-linear continuous prog-
nostic factors were included in the model using restricted cubic splines.
We chose the number of knots based on descriptive plots in the
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univariable analysis to provide a sufficient balance between capturing accur-
ate shape and without overfitting.30 We used three knots (a sensitivity ana-
lysis using five knots resulted in very similar predictions). Proportional
hazard assumptions were checked using residual and log(-log) plots.
For non-normally distributed continuous prognostic factors, sensible func-
tional form was obtained by log transformation. For parsimony, backwards
selection methods were employed for constructing multivariable models,
in which all prognostic factors were initially included, and removed step-
wise if P> 0.1. Variance inflation factors were calculated to detect evidence
of multicollinearity problems in the model selection process. Known im-
portant prognostic factors (age, gender, smoking status, index acute MI
subtype, diabetes, history of MI prior to index acute MI, and stroke) were
retained in all models. Missing values were multiply imputed using MICE
(Multiple Imputation by Chained Equations).31 Thirty imputed sets were
generated using all baseline covariates (demographics and behaviours, dis-
ease history, clinical biomarkers, and prescribed drugs) in the models.
Model validation
Models were validated using our geographically external North of England
population. Unequal sized groups can minimise information loss when cat-
egorising compared with equal groupings,32 we, therefore, grouped pa-
tients into four risk groups (highest, high, low, and lowest) using cut-points
at the 16th, 50th and 84th percentiles of the development cohort linear
predictor.33 C-indexes estimated models discrimination. Model calibration
was assessed visually by comparing plots of model expected events with
validation cohort observed events, stratified by the risk group.
Model application
We applied relative risks for efficacy (cardiovascular death, stroke, or MI)
and safety (TIMI major bleeding and fatal or intracranial bleeding) for tica-
grelor 60 mg vs. placebo from the PEGASUS-TIMI 54 trial4 to the valid-
ation cohort stratified by predicted risk groups to estimate the potential
events prevented and harms caused per 10 000 patients treated per year.
We assume constant treatment effect across risk groups. We calculated
net cardiovascular death, stroke, or MI and net CALIBER major bleeding
risks with treatment for each individual in the validation cohort using the
trial relative risk estimates. We evaluated predicted net benefit in patients
(i.e. estimated cardiovascular risk decrease exceeds bleeding risk in-
crease) under different benefit and harm weighting scenarios.9,34
Analyses were performed using R version 3.0.2.
Results
Baseline characteristics and overall event
rates
The model development cohort consisted of 12 694 patients (mean
age 70.1 years, 66.1% male) from 159 general practices, median follow-
up of 3.1 years (range: 0–9.8) and 27% followed-up for at least 5 years
(Table 1 and see Supplementary material online, Figure S1). The valid-
ation cohort consisted of 5613 patients (mean age 69 years, 64.4%
male) from 61 general practices. Overall, approximately 3% of patients
had prolonged clopidogrel use in follow-up. Patient characteristics of
the cohorts changed from acute MI discharge to our baseline of 1-year
post-MI including increased heart failure and renal disease prevalence
and changed smoking statuses (see Supplementary material online,
Table S4). The cardiovascular and bleeding event rates from one-year
post-MI in the development and validation cohorts are shown in
Supplementary material online, Figure S2.
.................................................................................................
Table 1 Characteristics of population-based samples
of patients at baseline defined as 1 year after their last
acute MI
Development
cohort
(n512 694)
Validation
cohort
(n55613)
Demographics and behaviours
Age (years) 70.1 (12.7) 69.1 (12.8)
Women 33.9% 35.6%
Ethnicity
Asian 2.0% 1.1%
Black 0.5% 0.1%
Other 17.0% 14.1%
White 80.4% 84.6%
Index of multiple deprivation
(highest quartile- most deprived)
15.4% 30.3%
Smoking status
Ex-smoker 49.3% 50.0%
Non-smoker 36.7% 34.2%
Smoker 14.0% 15.8%
Excess alcohol 10.8% 15.4%
Cardiovascular diseases
Index acute MI subtype
NSTEMI 32.1% 29.1%
STEMI 17.4% 16.4%
Unspecified 50.5% 54.5%
MI (prior to index acute MI) 34.7% 38.7%
Revascularisation (any) 43.5% 33.0%
Primary PCI for index acute MI 24.8% 18.8%
PCI at any time prior to
1 year post MI
39.4% 31.0%
CABG at any time to
1 year post MI
4.1% 2.0%
Stroke 6.9% 8.1%
Atrial fibrillation 18.0% 17.9%
Heart failure 23.5% 28.0%
Peripheral arterial disease 9.8% 13.1%
Renal disease 13.6% 14.8%
Recent hospitalisation for
acute renal disease
1.3% 1.0%
Non-cardiovascular diseases
Diabetes
Type 1 1.2% 0.9%
Type 2 16.7% 17%
Unspecified 1.5% 1.7%
COPD 9.1% 12.8%
Recent hospitalisation
for acute COPD
1.1% 2.2%
Liver disease 0.4% 0.5%
Non-metastatic cancer 14.4% 13.2%
Metastatic cancer 1.0% 1.2%
Dementia 1.3% 2.0%
Chronic anaemia 14.3% 17.9%
Peptic ulcer 7.3% 10.2%
Continued
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Development of prognostic models
In univariable (see Supplementary material online, Figure S3) and multi-
variable (Figure 1 and see Supplementary material online, Table S5) mod-
elling, we identified 20 prognostic factors for inclusion in our
cardiovascular death, stroke, or MI model and 18 prognostic factors for
inclusion in our three bleeding models. Prognostic factors were accept-
able under the proportional hazards assumption (see Supplementary
material online, Figure S4) and there was no evidence of problematic
multicollinearity between the prognostic factors in the multivariable
models (variance inflation factors < 3). Systolic blood pressure was
modelled using restricted cubic splines due to a non-linear (U-shaped)
relationship with the endpoints (see Supplementary material online,
Figure S5 and Table S6). The presence and direction of prognostic factor
associations with cardiovascular events and bleeding outcomes
were mostly concordant. The magnitude of prognostic factor associ-
ations (e.g. history of MI, stroke, diabetes) differed across endpoints.
Validation of prognostic models
For each endpoint, patients were divided into four risk groups (see
Supplementary material online, Table S7). The models discriminated
risk well (Figure 2), c-indexes of 0.75, 95% CI: 0.74, 0.77 for the com-
posite of cardiovascular death, stroke or MI, CALIBER major bleeding
(0.72, 95% CI: 0.67, 0.77), fatal or hospitalised bleeding (0.67, 95% CI:
0.64, 0.70), and fatal or intracranial bleeding (0.68, 95% CI: 0.61, 0.75).
Better performance was observed for the all-cause mortality (0.81,
95% CI: 0.80, 0.82) and cardiovascular mortality (0.81, 95% CI: 0.80,
0.83) models. The models were highly calibrated (Figure 2), in particu-
lar, models for cardiovascular events performed satisfactorily across
all risk groups.
Potential absolute benefits and harms in
risk groups
We observed higher event rates in our study cohort compared with
the trial placebo group for cardiovascular death, stroke, or MI (16.5%
vs. 9.04%) and major bleeding (CALIBER 1.7% vs. TIMI 1.26%) events.
Table 2 shows on an intention-to-treat basis in highest risk groups,
for every 10 000 patients treated per year, 249 (95% CI: 228, 269)
cardiovascular events may be prevented and 134 (95% CI: 87,181)
major bleeding events may be caused, whereas in the lowest risk
groups 28 (95% CI: 19, 37) cardiovascular events may be prevented
and 9 (95% CI: 0, 20) major bleeding events may be caused. In the ab-
sence of risk stratification, we estimated 89 (95% CI: 83, 94) cardio-
vascular events prevented and 42 (95% CI: 32, 51) harmed patients
per 10,000 treated per year. Fatal or intracranial bleeding occurred in
2.2% of high-risk patients and fatal or hospitalised bleeding occurred
in 10.5% of high-risk patients.
Potential net clinical benefits in
individuals
We estimated positive net clinical benefit in 93.5% of patients when
cardiovascular death, stroke, or MI events and CALIBER major bleed-
ing were weighted equally, 63% if avoiding major bleeding was valued
twice more than preventing cardiovascular events and 99.1% if pre-
venting cardiovascular events was valued twice as high as avoiding
major bleeding (Figure 3, panel A). We illustrate the importance of
using clinical characteristics updated at 1 year after acute MI (Figure 3,
panel B) compared with characteristics at acute MI discharge for five
patients. For example, using characteristics at discharge Patient 5
would be considered suitable for prolonged DAPT under all weight-
ing options (point ‘’ on the figure), whereas using updated informa-
tion 1 year post-MI, this patient would only be considered suitable
for prolonged DAPT if they valued potential benefits over potential
harms of treatment (point ‘’ on the figure).
Discussion
Using population-based linked EHRs, we developed and validated prog-
nostic models providing personalised estimates of risks of major cardio-
vascular and bleeding events in patients 12 months after an acute MI.
With trial relative risks, we estimated potential benefits and harms of
prolonged DAPT across risk groups. In individuals, potential net clinical
benefit was observed for the majority of patients, even when avoiding
.................................................................................................
Table 1 Continued
Development
cohort
(n512 694)
Validation
cohort
(n55613)
Bleeding diatheses and
coagulation disorders
1.1% 1.1%
Hospitalised bleeding 6.5% 8.2%
Treatments prescribed
Aspirin 87.0% 86.2%
Clopidogrel 50.5% 47.8%
Prolonged clopidogrel,
post-baseline
2.7% 3.4%
Oral anticoagulant 9.9% 9.5%
Statin 88.5% 88.6%
Anti-hypertensive 96.4% 96.0%
Biomarkers
BMI (Continuous) (kg/m2) 27.8 (5.1) 27.7 (5.1)
BMI (Categorical)
Underweight 1.5% 1.8%
Normal 28.7% 28.4%
Overweight 41.2% 42.2%
Obese 28.6% 27.7%
SBP (mmHg) 133 (18.6) 132 (18.4)
DBP (mmHg) 75.3 (10.4) 74.6 (10.1)
Haemoglobin (g/dl) 13.4 (1.6) 13.3 (1.6)
White blood cell count (109/l) 7.60 (2.3) 7.68 (2.3)
Total cholesterol (mmol/l) 4.17 (1.0) 4.17 (1.0)
HDL cholesterol (mmol/l) 1.28 (0.4) 1.26 (0.4)
Creatinine (lmol/l) Median (IQR) 98 (84, 114) 99 (86, 117)
eGFR (ml/min) 65.5 (20.3) 64.7 (20.7)
eGFR < 60 ml/min 38.7% 41.2%
Values are mean (SD) except where stated.
MI, myocardial infarction; STEMI, ST-elevation myocardial infarction; NSTEMI,
non-ST-elevation myocardial infarction; PCI, Percutaneous coronary intervention;
CABG, Coronary artery bypass graft; COPD, chronic obstructive pulmonary dis-
ease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration
rate.
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..bleeding is considered twice as important as preventing cardiovascular
events; however, the magnitude of benefit must also be considered.
Potential cardiovascular event
prevention
Our unselected study cohort experienced a much higher cardiovas-
cular event rate than the PEGASUS-TIMI 54 trial placebo group des-
pite the trial inclusion criteria enriching for high risk.35 Thus, the
potential absolute benefit of prolonged DAPT may be greater than
reported in the trial. Importantly, potential benefits are comparable
when the unselected real-world study population reported here is
restricted to those meeting the trial inclusion and exclusion criteria
(89 vs. 101 events potentially prevented per 10 000 treated per year,
respectively).35 Our models widely separated the risk of events: a
clinician may treat nine times (28/249) as many patients in the
lowest-risk, compared with the highest-risk group, to prevent one
cardiovascular event. Our models help clarify limitations of ignoring
individual patient characteristics evaluated during the stable phase
post-acute MI.
Potential bleeding harms
In balancing potential harms from prolonged DAPT, we show the im-
portance of considering different bleeding endpoints. While all bleed-
ings we studied may be considered serious (they all required
hospitalisation), their event rates and potential harms vary signifi-
cantly. We sought to approximate the PEGASUS-TIMI 54 trial pri-
mary safety endpoint, TIMI major bleeding, and successfully defined
fatal bleeding, intracranial bleeding and transfusions, but not, in cur-
rently available EHR, acute haemoglobin change. Nonetheless, inci-
dence of CALIBER major bleeding was comparable with TIMI major
bleeding in the trial placebo arm.
CV death, stroke or MI Fatal or hospitalised
 bleeding
CALIBER major
 bleeding
Fatal or intracranial
 bleeding
Alcohol abuse
Ex−smoker
Smoker
Non−smoker [ref]Ethnicity − Other
Ethnicity − Black
Ethnicity − Asian
Ethnicity − White [ref]Women
Age (per 5 years)
Unspecified diabetes
Type 2 diabetes
Type 1 diabetes
No diabetes [ref]Peripheral arterial disease
Stroke
Atrial fibrillation
Heart failure
Revascularisation (PCI or CABG)MI (prior to index)
Unspecified MI type
STEMI
NSTEMI [ref]
Hospitalised bleeding
Bleeding disorders
Peptic ulcer
Chronic anaemia
Dementia
Metastatic cancer
Cancer
Liver disease
Cholesterol ratio (HDL:total)log[Creatinine (mol/l)]
Haemoglobin (g/dL)White blood cell count (10^9/L)
BMI − Obese
BMI − Overweight
BMI − Normal [ref]BMI − Underweight
Oral anticoagulant use
Antiplatelet (exc. aspirin) use
D
em
ographics
 & beha
viours
Cardio
vascular history
N
on−cardio
vascula
r
 history
Biom
arkers
D
rug
s
−2 −1 0 1 2 −2 −1 0 1 2 −2 −1 0 1 2 −2 −1 0 1 2
log Hazard Ratio
Figure 1 Prognostic factors (multivariable) for 5-year cardiovascular death stroke or MI, fatal or hospitalised bleeding, CALIBER major bleeding
and fatal or intracranial bleeding endpoints. CV, cardiovascular; MI, myocardial infarction; ref, reference group; NSTEMI, non-ST-elevation myocardial
infarction; STEMI, ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; BMI, body mass
index; HDL, high-density lipoprotein; exc., excluding; log hazard ratios compared with [ref] group for categorical factors or per unit increase for con-
tinuous factors; for hazard ratios and 95% confidence intervals see Supplementary material online, Table S4. Systolic blood pressure was included in
all models using restricted cubic splines (see Supplementary material online, Table S5).
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Balancing potential benefits and harms in
individuals
Patients and clinicians differ in how they value different benefits and
harms, and we derived net clinical benefit estimates under different
weighting scenarios. These can inform patient counselling and pa-
tient–doctor discussions tailored to patients risk covariates. Cost-
effectiveness considerations are additionally important in determining
the magnitude of net clinical benefit a given health system is willing to
pay for.36,37
Need for multivariable risk prediction
The importance of tailoring risk to multiple patient characteristics, as
opposed to single risk factors (e.g. age, diabetes, history of MI and
renal disease)38 is illustrated in Supplementary material online, Figure
S6. In each case, the risk distribution largely overlaps among people
with and without simple binary prognostic factors. Furthermore,
while simple, point-based scores for predicting bleeding risk prove
valuable for other diseases,39,40 they are unlikely to be useful for this
population. For example, we found HASBLED7 performed poorly in
our stable post-MI cohort (c-index 0.57). It is well-known categoris-
ing clinical information loses predictive value and systolic blood pres-
sure has non-linear U-shaped associations with endpoints (see
Supplementary material online, Figure S5 and Table S6)41 consistent
with lower blood pressure reflecting impaired left ventricular
function and therefore higher risk. Nonetheless in practice some sim-
plification of our models will occur as absolute contraindications are
established (e.g. although we adjusted for history of bleeding in our
models, patients who bleed in the first year should be excluded from
the prolonged DAPT treatment option).
Application in clinical practice
We demonstrate marked changes in the year following acute MI in
the prevalence of major prognostic factors, including heart failure,
renal disease and smoking, with consequent changes in net benefits.
Good clinical practice dictates thorough evaluation of patients at the
time of decision-making including up-to-date medical history and bio-
markers. Our models can be readily implemented in health systems
with EHR.42 We present a web-based tool providing personalised
risk predictions at http://www.caliberresearch.org/prolonged_dapt_
benefits_harms_risks (10 January 2017).
Methodological strengths
Few, if any, previous studies evaluated prognostic relevance of clinical
data available at the decision point of surviving 1 year following an
acute MI. Previous studies focused on factors measured in the acute
hospitalised phase. Unlike voluntary disease registries or trial popula-
tions which may not reflect the entire population at risk, CALIBER is
population based. Therefore, estimates of risk obtained are likely to
be representative of those observed in usual clinical practice.
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Figure 2 Geographical validation; calibration of cardiovascular and bleeding prognostic models by risk group. CV, cardiovascular; MI, myocardial
infarction; CI, confidence interval.
Personalising the decision for prolonged dual antiplatelet therapy 1053
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Routinely collected clinical information readily available in EHR
enabled estimation of changing net clinical benefit of prolonged
DAPT during patient journeys. We have shown previously extensive
evidence of the diagnostic and prognostic validity of the EHR sources
in studies of acute myocardial infarction, stroke and bleeding
endpoints.14,16,17,23
Limitations
Our study has important limitations. First, the information that is re-
corded as part of usual clinical practice is unlikely to have the same
precision as that recorded as part of standardised research protocols.
If the quality of information recording is low, then this will diminish
the ability of the models to discriminate risk. Second, current large-
scale population-based EHR data lack information on left ventricular
function, number of diseased vessels, coronary stent type, and diam-
eter. However it is not known if such factors remain prognostically
relevant when included in models with updated clinical information
at 1-year post-MI. There is extensive evidence that stent type (bare
metal, drug eluting, and bioabsorbable) is an important predictor of
prognosis from the time of acute myocardial infarction, and this study
was unable to evaluate whether, in the stable phase 12 months after
acute myocardial infarction, at a time, when we demonstrate that
clinical factors have changed, stent characteristics continue to pro-
vide incremental discrimination of risk. Previous nationwide studies
of angiographic findings suggest only a modest predictor of subse-
quent events in stable patients.43 Furthermore, we did not validate
our models in different health systems. However, a study of 140 000
unselected stable post-MI patients found similar rates of cardiovascu-
lar and bleeding events in England, France, Sweden, and USA2 and the
effects of multiple prognostic factors reported in the present study
were consistent across these four countries, suggesting potential
geographic transportability of our models. We used multiple imput-
ations where appropriate and our complete-case sensitivity analysis
showed no important difference to our presented models. Multiply
imputing MI type for those unspecified did not show any difference to
the ST-elevation MI vs. non ST-elevation MI contrast presented in
our multivariable models.
Future research
We propose three major avenues for future research. First, further
validation studies are recommended in populations differing in back-
ground, treatment strategies, and event rates to ensure generalisabil-
ity.43 We selected a study period to provide a relatively pure
population, prior to the UK approval of ticagrelor and widespread
occurrences of prolonged DAPT. Further research is required to test
our models in more recent cohorts with a mix of clopidogrel, ticagre-
lor, and prasugrel users and risk prediction models may be required
for other harms (e.g. dyspnoea in patients taking ticagrelor). Second,
as with any prognostic model the question arises of what is their im-
pact on clinical outcomes and costs36,37 when implemented in clinical
care.44 This would involve developing clinical decision support sys-
tems using prognostic models, and evaluation through a cluster
.................................................................................................................
.......................................................................................
....................................................................................................................................................................................................................
Table 2 Estimated events prevented and harms caused per 10 000 patients treated per year with prolonged dual antipla-
telet therapy by predicted risk groups compared with all risk groups combined and the PEGASUS-TIMI 54 trial population
Unselected population Trial population
Risk groups as defined by prognostic models
in the validation cohort (n55613)
Lowest Low High Highest All PEGASUS-TIMI
54 placebo arm
Potential benefits
Cardiovascular death, stroke, or MI
3 year cumulative risk, % (95% CI) 5.2 (3.4, 6.9) 6.3 (5.0, 7.5) 17.1 (15.2, 19.0) 46.7 (42.7, 50.3) 16.5 (15.4, 17.6) 9.04
Events potentially prevented (95% CI) (ITT) 28 (19, 37) 34 (27, 41) 92 (81, 102) 249 (228, 269) 89 (83, 94) 42
Potential harms
CALIBER major bleeding
3-year cumulative risk, % (95% CI) 0.3 (0.0, 0.8) 1.0 (0.5, 1.5) 1.4 (0.8, 2.0) 5.4 (3.5, 7.2) 1.7 (1.3, 2.0) 1.26a (ITT);
1.06a (OT)
Harms potentially caused (95% CI) (ITT) 9 (0, 20) 26 (14, 39) 36 (21, 51) 134 (87, 181) 42 (32, 51) 31
Harms potentially caused (95% CI) (OT) 15 (0, 35) 46 (24, 68) 63 (36, 89) 236 (153, 318) 73 (56, 90) 47
Fatal bleeding or intracranial bleeding
3- year cumulative risk, % (95% CI) 0 0.7 (0.3, 1.1) 1.1 (0.5, 1.6) 2.2 (0.9, 3.4) 0.9 (0.6, 1.2) 0.60
Harms potentially caused (95% CI) (OT) – 5 (2, 8) 8 (4, 11) 15 (7, 23) 7 (5, 9) 4
Fatal or hospitalised bleeding
3-year cumulative risk, % (95% CI) 1.4 (0.5, 2.3) 3.3 (2.4, 4.3) 5.8 (4.5, 7.0) 10.5 (8.0, 13.0) 4.9 (4.3, 5.6) Not availableb
Note: PEGASUS-TIMI 54 trial estimated relative risks [ticagrelor 60 mg vs. placebo; intention-to-treat (ITT) and on treatment (OT) estimates where available] for cardiovascular
death, stroke, or MI [ITT: 0.84, main report], TIMI major bleeding [ITT: 1.75, appendix E; OT: 2.32, main report], fatal bleeding or intracranial bleeding [OT:1.20, main report]
were used to calculate CV events potentially prevented and harms potentially caused per 10 000 treated per year.
aTIMI-major bleeding.
bNo broad/composite bleeding endpoint reported in PEGASUS-TIMI 54.
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randomised controlled trial. Third, there is a need to identify bio-
markers which distinguish bleeding from cardiovascular event risks
and may further aid decision-making.
Conclusion
Using population-based EHRs, we developed and validated prognos-
tic models for benefits and different bleeding harms, relevant to the
decision to prolong DAPT in patients stable 1 year after an acute MI.
Personalised treatment decisions, based on individual patient risk
profiles, can inform decision-making.
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